Hormone Receptor-positive/Her2 Negative Breast Cancer

Explore clinical trials studying Hormone Receptor-positive/Her2 Negative Breast Cancer. Study availability and eligibility vary by location and protocol.

1 public trial 1 recruiting study

Refine in advanced search Browse all conditions

Hormone Receptor-positive/Her2 Negative Breast Cancer trial results

Recruiting

Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)

NCT05579366

Conditions: Adenoma, Adnexal Diseases, Breast Adenocarcinoma, +49 more
Locations: USOR HonorHealth Phoenix, Arizona, United States

USOR Arizona Oncology Associates Tucson, Arizona, United States

University of California Los Angeles Medical Center Los Angeles, California, United States

University of California, San Diego; Moores Cancer Center San Diego, California, United States

View all 66 locations

View Trial Details

Adenoma (1)
Adnexal Diseases (1)
Breast Adenocarcinoma (1)
Breast Diseases (1)
Breast Neoplasms (1)
Bronchial Neoplasms (1)
Carcinoma, Bronchogenic (1)
Carcinoma, Non-Small-Cell Lung (1)

Hormone Receptor-positive/Her2 Negative Breast Cancer

Hormone Receptor-positive/Her2 Negative Breast Cancer trial results

Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)

Related conditions